EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Proton Radiotherapy for Vestibular Schwannomas in Patients with NF2-Related Schwannomatosis: A Case Series

Jules P J Douwes iD, Kimberley S Koetsier, Victor S van Dam, Scott R Plotkin, Frederick G Barker, D Bradley Welling iD, Jeroen C Jansen iD, Erik F Hensen iD, Helen A Shih

Current Oncology · 2023

DOI: 10.3390/curroncol30030263 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2023. Verfasst von Jules P J Douwes und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology-Head and Neck Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands. Hauptthemen laut MEDLINE: Neuroma, Acoustic, Neurofibromatosis 2, Tinnitus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Economic Affairs and Climate and the HollandPTC consortium—Erasmus MC, Rotterdam.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

(1)

Background

This study aimed to evaluate the efficacy and treatment-related toxicity of proton radiotherapy (PRT) for vestibular schwannoma (VS) in patients with neurofibromatosis type 2-related schwannomatosis (NF2). (2)

Methods

Consecutive NF2 patients treated with PRT for VS between 2004 and 2016 were retrospectively evaluated, focusing on tumor volume, facial and trigeminal nerve function, hearing, tinnitus, vestibular symptoms, and the need for salvage therapy after PRT. (3)

Results

Eight patients were included (median age 36 years, 50% female). Median follow-up was 71 months. Five (63%) patients received fractionated PRT and three (38%) received PRT radiosurgery for VS. Six patients (75%) received prior VS surgery; three also received bevacizumab. Six patients (75%) did not require salvage therapy after PRT. Two patients (25%) with residual hearing lost it after PRT, and six had already lost ipsilateral hearing prior to PRT. Tumor and treatment-related morbidity could be evaluated in six patients. Following PRT, conditions that occurred or worsened were: facial paresis in five (83%), trigeminal hypoesthesia in two (33%), tinnitus in two (33%), and vestibular symptoms in four patients (67%). (4)

Conclusion

After PRT for VS, the majority of the NF2 patients in the cohort did not require additional therapy. Tumor and/or treatment-related cranial nerve deficits were common. This is at least partly explained by the use of PRT as a salvage treatment after surgery or bevacizumab, in the majority of cases. There remains the further opportunity to elucidate the efficacy and toxicity of proton radiotherapy as a primary treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroma, AcousticNeurofibromatosis 2TinnitusAdultMaleBevacizumabProtonsNeurilemmomaNeurofibromatosesFemaleHumansTreatment OutcomeRetrospective StudiesSkin NeoplasmsFollow-Up Studies

Stichwörter der Autor:innen

acoustic neuromacranial nervehearingneurofibromatosis type 2proton radiotherapyschwannomatosistoxicityvestibular schwannoma

Substanzen

ProtonsBevacizumab

Autor:innen und Institutionen

  • Department of Otorhinolaryngology-Head and Neck Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
  • Department of Otorhinolaryngology-Head and Neck Surgery, Erasmus MC, 3015 GD Rotterdam, The Netherlands.
  • Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
  • Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
  • Department of Otorhinolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA 02114, USA.
  • Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

ORCID-Profile: Jules P J Douwes, D Bradley Welling, Jeroen C Jansen, Erik F Hensen

Förderung

  • Ministry of Economic Affairs and Climate and the HollandPTC consortium—Erasmus MC, Rotterdam

Zitieren

APA

Douwes, J. P. J., Koetsier, K. S., van Dam, V. S., Plotkin, S. R., Barker, F. G., Welling, D. B., Jansen, J. C., Hensen, E. F., & Shih, H. A. (2023). Proton Radiotherapy for Vestibular Schwannomas in Patients with NF2-Related Schwannomatosis: A Case Series. Current Oncology. https://doi.org/10.3390/curroncol30030263

Vancouver

Douwes JPJ, Koetsier KS, van Dam VS, Plotkin SR, Barker FG, Welling DB, et al. Proton Radiotherapy for Vestibular Schwannomas in Patients with NF2-Related Schwannomatosis: A Case Series. Current Oncology. 2023. doi:10.3390/curroncol30030263

BibTeX
@article{Douwes2023,
  author = {Douwes, Jules P J and Koetsier, Kimberley S and van Dam, Victor S and Plotkin, Scott R and Barker, Frederick G and Welling, D Bradley and Jansen, Jeroen C and Hensen, Erik F and Shih, Helen A},
  title = {Proton Radiotherapy for Vestibular Schwannomas in Patients with NF2-Related Schwannomatosis: A Case Series},
  journal = {Current Oncology},
  year = {2023},
  doi = {10.3390/curroncol30030263}
}
Kostenlos starten →